Based on an anorexic effect of the MCH peptide and the lean phenotypes of the MCH-deficient and MCHR1-deficient mice, MCHR1 antagonists have been recognized as attractive targets for the treatment of obesity. This evidence concerns the gene PMCH and obesity due to melanocortin 4 receptor deficiency.